Glenmark Pharmaceuticals Limited has secured a significant regulatory milestone with the United States Food & Drug Administration (U.S. FDA) granting final approval for its Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC). This approval positions the company to enter a substantial over-the-counter allergy relief market worth hundreds of millions of dollars.

FDA Approval and Product Details

The FDA has determined that Glenmark's Fluticasone Propionate Nasal Spray USP is bioequivalent to the reference listed drug, Flonase® Allergy Relief Nasal Spray, 50 mcg per spray, manufactured by Haleon US Holding LLC. The product will be distributed in the United States by Glenmark Therapeutics Inc., USA, marking a strategic expansion into the OTC nasal spray segment.

Market Opportunity and Commercial Potential

According to Nielsen® syndicated data for the latest 52-week period ending March 3, 2026, the Flonase® Allergy Relief Nasal Spray market achieved annual sales of approximately $384.7 million. This substantial market size represents a significant commercial opportunity for Glenmark's newly approved product.

The market data includes brand and all available therapeutic equivalents, providing a comprehensive view of the competitive landscape that Glenmark will be entering with its bioequivalent formulation.

Management Commentary and Strategic Significance

Marc Kikuchi, President & Business Head, North America, expressed enthusiasm about the approval, stating: "We are excited to announce the recent approval of Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC). As the first approved nasal spray distributed by Glenmark Therapeutics Inc., USA in the OTC space, we look forward to bringing this quality over-the-counter solution to our customers when we launch in April 2026."

This launch represents several strategic milestones for the company:

• First nasal spray product in Glenmark's OTC portfolio in the US market
• Entry into the substantial allergy relief segment
• Expansion of the company's over-the-counter product offerings
• Strengthening of Glenmark Therapeutics Inc., USA's distribution capabilities

Company Profile and Global Presence

Glenmark Pharmaceuticals Ltd. operates as a global, research-led pharmaceutical company with a focus on innovation and accessibility. The company maintains 11 world-class manufacturing facilities across four continents, supported by six cutting-edge R&D centres, and maintains a commercial footprint in over 80 countries.

The company delivers a diversified portfolio across branded, innovative, generics, and consumer health products, with particular focus on respiratory, dermatology, and oncology therapeutic areas. Scrip 100 positions Glenmark among the Top 100 biopharmaceutical companies globally by pharmaceutical sales for 2024.

Glenmark Pharmaceuticals Inc., USA has announced the upcoming launch of Potassium Phosphates Injection USP in multiple vial formats, with distribution scheduled to begin in March 2026. The company filed regulatory notifications with BSE and NSE on March 16, 2026, detailing this strategic expansion of its injectable pharmaceutical portfolio in the United States.

Product Launch Specifications

The launch encompasses three distinct vial formats of Potassium Phosphates Injection USP, each designed for specific clinical applications. The product is bioequivalent and therapeutically equivalent to Fresenius Kabi's reference listed drug.

Market Opportunity and Sales Potential

According to IQVIA sales data for the 12-month period ending January 2026, the Potassium Phosphates Injection USP market achieved annual sales of approximately $50.7 million. This figure represents the total market opportunity including brand and all available therapeutic equivalents across the three vial formats.

Leadership Commentary

Marc Kikuchi, President & Business Head, North America, emphasized the strategic importance of this launch for the company's institutional channel growth. "We look forward to growing our portfolio of products within the institutional channel with the upcoming launch of Potassium Phosphates Injection USP," Kikuchi stated. "We continue to strengthen our commitment to bring quality and affordable alternatives to market for patients in need with each injectable launch."

Strategic Significance

This product launch reinforces Glenmark Pharmaceuticals' commitment to expanding its injectable product portfolio in the United States healthcare market. The comprehensive vial format offering addresses diverse clinical needs, from single-dose applications to pharmacy bulk packaging for institutional use. The March 2026 launch timeline positions the company to capture market share in this established therapeutic segment while providing healthcare providers with bioequivalent alternatives to existing treatments.